ABSTRACT
Background. Monoclonal antibodies for the outpatient treatment of the novel Coronavirus Disease 2019 (COVID-19) first received emergency use authorization from the Food and Drug Administration in November 2020. These antibodies have been associated with a reduction in emergency department visits and hospitalization through randomized controlled trials. However, modest data is available to describe the outcomes of patients who were hospitalized despite treatment. This study describes real-world outcomes concerning the treatment of COVID-19 with the first approved monoclonal antibody for COVID-19, bamlanivimab, as well as hospital courses associated with patients admitting after receiving the therapy. Methods. This single-center, retrospective study evaluated real-world data of patients treated with bamlanivimab. The primary endpoint was a composite of emergency department (ED) visits or hospitalization due to worsening COVID-19. Data was analyzed from November 23, 2020 to March 5, 2021. Descriptive statistics were used to analyze the primary endpoint. Secondary endpoints include reported symptoms 24-hours post-infusion and time to symptom resolution in days. Additionally, clinical course of patients hospitalized were analyzed and include average oxygen requirements, median length of stay, and mortality. A subgroup analysis was conducted between patients less than sixty-five years of age and those sixty-five and older. Results. 619 patients received bamlanivimab during the specified timeframe. The primary endpoint occurred in 34 patients;11 ED visits and 23 hospitalizations. Baseline characteristics of the patients hospitalized include median age 69 years (IQR 55, 74), 56.5% male, and 82.6% Caucasian. The most common risk factors for severe disease among those hospitalized were age ≥ 65 years and history of diabetes. The clinical course of hospitalized patients varied but 52.9% required nasal cannula for respiratory support and the average length of stay was 4.5 + 4.5 days. Other COVID-19 therapies included dexamethasone in 76.5% of patients and remdesivir in 47.1% of patients. There were no major differences in the subgroup analysis. Conclusion. Bamlanivimab appears to attenuate the clinical course of COVID-19 in patients who are hospitalized despite treatment.
ABSTRACT
The Third International Workshop on Adaptive and Personalized Privacy and Security (APPS 2021) aims to bring together researchers and practitioners working on diverse topics related to understanding and improving the usability of privacy and security software and systems, by applying user modeling, adaptation and personalization principles. Our special focus in 2021 is on challenges and opportunities related to the Covid-19 outbreak, more specifically on ensuring security and privacy of sensitive data and secure user interactions in online systems. The third edition of the workshop includes interdisciplinary contributions from Belgium, Cyprus, Germany, Greece, Portugal, the Netherlands, and United Kingdom, that introduce new and disruptive ideas, suggest novel solutions, and present research results about various aspects (theory, applications, tools) for bringing user modeling, adaptation and personalization principles into privacy and systems security. This summary gives a brief overview of APPS 2021, held online in conjunction with the 29th ACM Conference on User Modeling, Adaptation and Personalization (ACM UMAP 2021). © 2021 Owner/Author.